These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1474 related articles for article (PubMed ID: 19237898)

  • 1. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
    Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
    Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
    J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients.
    Rafati MR; Rouini MR; Mojtahedzadeh M; Najafi A; Tavakoli H; Gholami K; Fazeli MR
    Int J Antimicrob Agents; 2006 Aug; 28(2):122-7. PubMed ID: 16815689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
    Roberts JA; Boots R; Rickard CM; Thomas P; Quinn J; Roberts DM; Richards B; Lipman J
    J Antimicrob Chemother; 2007 Feb; 59(2):285-91. PubMed ID: 17135183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
    Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
    Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily serum piperacillin monitoring is advisable in critically ill patients.
    Blondiaux N; Wallet F; Favory R; Onimus T; Nseir S; Courcol RJ; Durocher A; Roussel-Delvallez M
    Int J Antimicrob Agents; 2010 May; 35(5):500-3. PubMed ID: 20226635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
    Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
    Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis.
    Roberts JA; Roberts MS; Robertson TA; Cross SE; Lipman J
    Int J Antimicrob Agents; 2008 Mar; 31(3):240-4. PubMed ID: 18054829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Starr T; Udy AA; Paul SK; Lipman J; ;
    Crit Care Resusc; 2013 Sep; 15(3):179-85. PubMed ID: 23944203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.
    Dulhunty JM; Roberts JA; Davis JS; Webb SA; Bellomo R; Gomersall C; Shirwadkar C; Eastwood GM; Myburgh J; Paterson DL; Lipman J
    Clin Infect Dis; 2013 Jan; 56(2):236-44. PubMed ID: 23074313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
    Hoff DS; Wilcox RA; Tollefson LM; Lipnik PG; Commers AR; Liu M
    Pharmacotherapy; 2009 Nov; 29(11):1297-305. PubMed ID: 19857147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course.
    Carlier M; Carrette S; Stove V; Verstraete AG; De Waele JJ
    Int J Antimicrob Agents; 2014 May; 43(5):470-3. PubMed ID: 24685990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 74.